GlySure Presents Successful Medical ICU Study Results at ESICM
GlySure September 2014
Data reveals truly continous glucose sensor delivers clinically relevant accuracy throughout length of stay in critically ill patients.
GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, announced that Dr. Gopal Palepu is presenting the results of his Medical Intensive Care Unit (MICU) study at the European Society of Intensive Care Medicine (ESICM) 27th Annual Congress, September 27 - October 1, 2014 in Barcelona.
The investigators had previously trialled GlySure's technology within a cardiac surgery patient population. In this current study, entitled "Application of a Continuous Intravascular Blood Glucose Sensor to a MICU patient population," they extended their investigations to include potentially more challenging MICU patients, where the stimulated immune system, compromised organ function and poor perfusion of the critically ill can challenge the ability to generate accurate continuous blood glucose readings.
The researchers compared the accuracy of the GlySure system versus intermittent blood glucose measurement in 20 patients admitted in 10 MICUs across six hospitals from the time of admission to the time of discharge. The patients were between 26 and 85 years of age with diverse conditions, including pneumonia, sepsis, acute gastroenteritis, hemoperitoneum, chronic kidney disease, CAD, cerebral vascular accident, meningitis, acute pancreatitis and polytrauma.
The data revealed that GlySure's truly continuous intravascular sensor generated clinically relevant accuracy (MARD 9.5% with 88.2% in the A zone and 100% in the A+B zone of the Consensus Error Grid) that could optimise glucose management throughout the length of stay in critically ill patients.
"This is a significant step in demonstrating the ability to accurately and continuously monitor blood glucose across all ICU patients," said Principal Investigator Dr. Gopal Palepu. "An easy-to-use, accurate CBGM system will enable us to provide more effective glucose control on our critically ill patients."